Novo heralds promising PhIII diabetes data for once-weekly semaglutide

John Carroll Novo Nordisk is touting the first Phase III success for its once-weekly GLP-1 therapy semaglutide. The Danish pharma company says that two doses of the drug–a key ...

Big data tells J&J that recent grads are more loyal than experienced hires

Eric Palmer The "people analytics team" at drugmaker Johnson & Johnson used big data analysis techniques on employees to figure out whether hiring people with experience ...

Pfizer’s breast cancer-fighter Ibrance posts stellar second-line survival data

Carly Helfand Last month, Pfizer announced it had cut short its PALOMA-3 trial thanks to impressive second-line data for new cancer-fighter Ibrance. And now, industry-watchers have ...

New standout Imbruvica data bode well for market expansion in CLL

Carly Helfand Johnson & Johnson and AbbVie's Imbruvica has already shown in one Phase III study that it can extend progression-free survival in patients with previously treated ...

Big shot investor plans £100M EU biotech fund, Genmab up on PhII data, J&J inks U.K. RA deal

Nick Paul Taylor In this week's EuroBiotech Report, after years of relying heavily on Neil Woodford's checkbook, early-stage British and European biotechs could soon have another ...

Battered ArQule shares bump up on badly needed positive data for tivantinib

John Carroll ArQule's badly battered shares managed a quick surge this morning on news that the biotech's lead drug tivantinib scored a positive outcome in a Phase II metastatic ...

Japan unveils sunshine data of its own, raising eyebrows after Diovan scandal

Tracy Staton Just as the dust is settling after the big rollout of doctor-payment data in the U.S., a new round has made its debut–in Japan. According to The Japan News, the country's ...

Merck and Roche prep breast cancer data for promising PD-1 drugs

Emily Mullin As fervor surrounding a new class of cancer drugs builds, drug giants Merck and Roche are set to roll out new data for their opposing immunotherapy drugs for breast cancer ...

EMA adopts open trial data policy to begin Jan. 1

Emily Mullin The European Medicines Agency adopted a new policy on Oct. 2 that requires drug companies to make public certain clinical data that predicate drug approvals. FierceBiotech ...

Lilly says with new data, it will seek another approval for Cyramza next year

Eric Palmer Eli Lilly has harbored big hopes for its newly approved cancer fighter Cyramza. It expects it to get a string approvals, and with new data in hand, it said it will go to ...

Novartis’ LCZ696 kindles megablockbuster projections with impressive PhIII heart data

John Carroll Novartis told the world back in March that its experimental heart drug LCZ696 had delivered the goods early in a pivotal study, allowing for a quick wrap of the Phase III ...

Sanofi, Regeneron point to potential heart benefit in PCSK9 data dump

John Carroll FierceBiotech News
Page 2 of 1212345...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS